Rifaximin, derived from rifamycin, is a broad-spectrum antibiotic by inhibiting bacterial RNA
synthesis. Rifaximin has a very low intestinal absorption and exerts its antimicrobial activity …

Introduction Management of the patient with cirrhosis of the liver that requires surgical
treatment has been relatively unexplored. In Mexico, there is currently no formal stance or …

RFX, a rifamycin-based antibacterial agent obtained by the culture of the actinomycete
Streptomyces mediterranei, has a broad antibacterial spectrum covering gram-positive …

Cirrhosis is a prevalent condition affecting more than 100 million people globally and
carrying significant morbidity and mortality related to the development of portal hypertension …

Type 2 diabetes mellitus (T2DM) and liver cirrhosis are clinical entities that frequently
coexist, but glucose‐lowering medication options are limited in cirrhotic patients. Sodium …

The incidence of hepatocellular carcinoma (HCC) has been rising, particularly among
individuals diagnosed with metabolic dysfunction-associated steatotic liver disease. In the …

BACKGROUND: Spontaneous bacterial peritonitis (SBP) represents a critical and potentially
lethal condition that typically develops in individuals with liver cirrhosis. This meta-analysis …

特利加压素是血管加压素的一种人工合成类似物, 已被广泛用于治疗急性静脉曲张破裂出血及肝
肾综合征等肝硬化并发症. 然而, 特利加压素的不同输注方式可能会造成其疗效和安全性有所 …

Background: Liver fibrosis arises from chronic hepatic injury and involves the accumulation
of extracellular matrix proteins. Fibrosis progression ultimately leads to cirrhosis …

The approach to risk stratification of cardiovascular disease in end-stage liver disease is
outlined, incorporating the AHA/ACC scientific statement on evaluation of cardiac disease in …